Back to Browse Journals » Cancer Management and Research » Volume 4

Importance of antiresorptive therapies for patients with bone metastases from solid tumors

Authors Talreja DB

Published Date September 2012 Volume 2012:4 Pages 287—297

DOI http://dx.doi.org/10.2147/CMAR.S33983

Received 18 May 2012, Accepted 7 July 2012, Published 11 September 2012

Draupadi B Talreja

Department of Medicine, David Geffen School of Medicine at UCLA and Northridge Hospital Medical Center, Northridge, CA, USA

Abstract: Patients with bone metastases are at risk of skeletal-related events such as pathologic fractures, spinal cord compression, the need for orthopedic surgery to bone, and palliative radiotherapy for severe bone pain. Antiresorptive therapies have demonstrated efficacy for reducing the risk of skeletal-related events and ameliorating bone pain. Despite the well documented clinical benefits of antiresorptive therapies, patient benefits can be limited or compromised by nonadherence with scheduled therapy. Potential reasons for poor compliance include lack of understanding of how antiresorptive therapies work, neglecting the importance of bone health in maintaining quality of life, and being unaware of the potentially debilitating effects of skeletal-related events caused by bone metastases. Indeed, patients may stop therapy after bone pain subsides or discontinue due to generally mild and usually manageable adverse events, leaving them at an increased risk of developing skeletal-related events. In addition, the cost of antiresorptive therapy can be a concern for many patients with cancer. Medical care for patients with cancer requires a coordinated effort between primary care physicians and oncologists. Patients' medical care teams can be leveraged to help educate them about the importance of adherence to antiresorptive therapy when cancer has metastasized to bone. Because primary care physicians generally have more contact with their patients than oncologists, they are in a unique position to understand patient perceptions and habits that may lead to noncompliance and to help educate patients about the benefits and risks of various antiresorptive therapies in the advanced cancer setting. Therefore, primary care physicians need to be aware of various mechanistic and clinical considerations regarding antiresorptive treatment options.

Keywords: antiresorptive therapy, bisphosphonates, bone metastases, cancer, denosumab, zoledronic acid

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Neuroinflammation in Alzheimer’s disease

Zhang FJ, Jiang LL

Neuropsychiatric Disease and Treatment 2015, 11:243-256

Published Date: 30 January 2015

Laser treatment of port-wine stains

Brightman LA, Geronemus RG, Reddy KK

Clinical, Cosmetic and Investigational Dermatology 2015, 8:27-33

Published Date: 12 January 2015

Managing comorbidities in COPD

Hillas G, Perlikos F, Tsiligianni I, Tzanakis N

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:95-109

Published Date: 7 January 2015

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus

Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA

Vascular Health and Risk Management 2015, 11:35-48

Published Date: 6 January 2015

Isolated posterior uveal effusion: expanding the spectrum of the uveal effusion syndrome

Pautler SE, Browning DJ

Clinical Ophthalmology 2015, 9:43-49

Published Date: 30 December 2014

Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients

Huang YS, Feng YC, Zhang J, Bai L, Huang W, Li M, Sun Y

Clinical Interventions in Aging 2015, 10:81-87

Published Date: 19 December 2014

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012